Press Releases

January 7, 2021
Tempest Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 8, 2021
Tempest Therapeutics to Present at the H.C. Wainwright Virtual Bioconnect Conference

October 21, 2020
Sam Whiting, M.D., Ph.D., Joins Tempest as Executive Vice President and Chief Medical Officer

July 31, 2020
Tempest Therapeutics to Present at Two Investor Conferences in August

June 22, 2020
Tempest Therapeutics Announces First Patient Dosed with the Combination of TPST-1120 Plus Nivolumab in a Phase 1 Study in Patients with Advanced Solid Tumors

May 7, 2020
Tempest Therapeutics Announces First Patient Dosed in TPST-1495 Clinical Study: Dual Ep2/4 Antagonist Targeting Solid Tumors

February 24, 2020
Tempest Therapeutics to Present at 9th Annual SVB Leerink Global Healthcare Conference

January 30, 2020
Tempest Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPST-1495 and Welcomes New Investors

November 8, 2019
Tempest Therapeutics’ Oncology Programs Presented at Society of Immunotherapy for Cancer Annual Meeting

October 7, 2019
Tempest Therapeutics Names Biopharmaceutical Executive Stephen Brady As President and Chief Operating Officer

October 2, 2019
Tempest Therapeutics Announces Multiple Presentations at Upcoming SITC 34th Annual Meeting

May 16, 2019
Tempest Therapeutics Starts Phase I/Ib Clinical Trial with First-In-Class PPAR Alpha Antagonist

November 13, 2018
Tempest Therapeutics Reports Proof of Mechanism Data for First‐In‐Class PPAR Alpha Antagonist

March 28, 2018
Tempest Therapeutics Closes $70 Million Series B Financing